Skip to content
Friday 14 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 07 January 2015 5:47 am

Silicon Valley was right to invest in DNA: Facebook and Google-backed personal genetics business strikes $10m deal with Genentech

By: Sarah Spickernell

Add as a preferred source on Google

Facebook and Google will be pleased about their decision to invest in personal genetics business 23andMe.
 
The firm, which sells DNA testing kits to individual customers for $99 (£65) each, has secured a major deal with Genentech – a subsidiary of Roche. 
 
According to Forbes, 23andMe is receiving an upfront payment from Genentech of $10m, with further payments of as much as $50m to follow. 
 
The biotech firm was attracted to 23andMe because of the access the deal will provide to a whole wealth of personal DNA data: nearly all of 23andMe's 800,000 customers agreed to have their sequenced genome donated for third party research.  
 
In the case of Genentech, the data will be used to study Parkinson's disease – a hereditary disorder which causes the central nervous system to stop working properly. 12,000 Parkinson's patients and 1,300 of their family members have signed up to 23andMe. 

ATTRACTING DEALS ACROSS THE SECTOR

Genetech is not the only firm to have a keen interest in the DNA database – 23andMe has signed nine other deals with large biotech and pharmaceutical companies. In fact, the company has been collaborating with businesses in the sector since it was founded in 2006. 
 
Last year, it signed a contract with American giant Pfizer to enroll over 10,000 bowel disorder patients. These people will help Pfizer study the genetic causes of diseases such as colitis or Crohn’s disease.
 
“I think that this illustrates how pharma companies are interested in the fact that we have a massive amount of information,” 23andMe's co-founder and chief executive Anne Wojcicki told Forbes.
 
“We have a very engaged consumer population, and these people want to participate in research. And we can do things much faster and more efficiently than any other research means in the world.”
 
From 23andMe's point of view, the revenue brought in by these major deals is much higher than the payments received from customers who buy the personal DNA testing kits. Just one of these deals can bring in twice as much money as all of the business's customer base. 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Facebook
  • Google

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • It’s not just Jason Arday, most of sociology is a scam

More from Morning Wire

  • DNA Payments Launches DNA Engage, a New Way for Businesses to Connect With Customers

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Exclusive: Blackstone set to back AI ‘droid’ firm at $3.5bn valuation

    AI
    Blackstone skyscraper with modern architecture under clear blue sky, symbolizing financial power and urban development.
  • Mike Ashley’s Frasers snaps up Harvey Nichols 

    Retail
    Exterior view of the Harvey Nichols department store building facade with detailed windows and architectural columns
  • Santander Financial Crime Transformation Leader Joins ThetaRay to Drive Enterprise AI Adoption

    Business Wire
  • Sainsbury’s to sell Argos in £120m cut-price deal

    Retail
    Sainsburys supermarket entrance with prominent Argos and Lloyds Pharmacy signs, reflecting the companys acquisitions.
  • Aston Villa sign £20m a year Visit Rwanda shirt sponsor deal

    Sport Business
    Breaking news event with a diverse group of professionals collaborating in a modern conference room setting
  • ActiveCampaign Launches Google Ads Connector for Active Intelligence, Bringing AI-Guided Campaign Creation and Reporting to Marketers

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook